Welcome to our dedicated page for Arcus Biosciences SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Arcus Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Arcus Biosciences's regulatory disclosures and financial reporting.
Arcus Biosciences General Counsel Carolyn C. Tang exercised stock options to acquire 34,090 shares of common stock at $2.574 per share on June 11, 2026. This was a derivative exercise, not an open-market purchase.
The fully vested option was completely exercised, leaving no remaining options from this grant. Following the transaction, Tang directly holds 184,607 common shares, which include 1,783 shares purchased through the company’s Employee Stock Purchase Plan and unvested RSU awards.
Arcus Biosciences director David L. Lacey received new equity awards on common stock. He was granted 5,700 restricted stock units, increasing his direct common stock holdings to 76,652 shares after the award.
He also received a stock option for 16,900 shares with an exercise price of $23.30 per share, expiring on June 10, 2036. Both the RSUs and the option vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and each will become fully vested if the company is subject to a change in control.
Arcus Biosciences director Kathryn E. Falberg reported new equity awards and updated her share holdings. She received 5,700 shares of Common Stock as restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and accelerate upon a change in control.
Falberg also received a stock option covering 16,900 shares at an exercise price of $23.30 per share, with the same vesting and change-in-control terms. After these awards, she holds 44,300 shares directly and 132,106 shares indirectly through a trust, which now includes 30,000 shares reclassified from direct ownership.
Arcus Biosciences director Antoni Ribas reported new equity awards and updated his holdings. He received 5,700 shares of Common Stock as restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and they fully vest if the company undergoes a change in control. He was also granted a stock option for 16,900 shares at an exercise price of $23.30 per share, with the option vesting on the same schedule and also accelerating upon a change in control. Following these awards, Ribas directly owns 44,300 Common Stock shares and holds an additional 8,553 shares indirectly through a trust.
Arcus Biosciences director Andrew J. Perlman received new equity awards as part of his compensation. He was granted 5,700 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and will fully vest if the company undergoes a change in control. Following this grant, he holds 48,325 Common Shares directly. Perlman also received a stock option covering 16,900 shares at an exercise price of $23.30 per share, vesting on the same schedule and expiring on June 10, 2036, with full vesting upon a change in control. These awards are compensation-related grants rather than open-market purchases or sales.
Arcus Biosciences, Inc. held its annual meeting of stockholders on June 11, 2026, where all management proposals were approved. Stockholders elected four Class II directors—Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier—to serve until the 2029 annual meeting and until their successors are duly elected and qualified.
Shareholders also ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
Arcus Biosciences, Inc. Chief Accounting Officer Alexander Azoy reported an open-market sale of 2,562 shares of common stock. The shares were sold at a weighted average price of $25.7704 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Azoy directly holds 39,581 shares, which include unvested restricted stock unit grants.
Arcus Biosciences director Antoni Ribas reported a routine insider update. He made a bona fide gift of 5,050 shares of Common Stock, described as a gift to family members for estate planning purposes. This transfer is a disposition but not a market sale, with no price received.
After the gift, Ribas directly holds 38,600 Common Stock shares, and separately has 8,553 shares held indirectly by a trust. A footnote notes that his indirect holdings include the unvested portion of his RSU grants, indicating ongoing equity exposure through both direct and indirect ownership.
Arcus Biosciences Chief Financial Officer Robert C. Goeltz II reported an open-market sale of 7,763 shares of common stock at $25.63 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, he holds 84,161 shares, including unvested RSUs.